Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ABO incompatible kidney transplantation.

James M Gloor1, Mark D Stegall

  • 1Department of Internal Medicine, Division of Nephrology and Hypertension and Transplant Center, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA. gloor.james@mayo.edu

Current Opinion in Nephrology and Hypertension
|December 20, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Abdominal Arterial Calcification as an Imaging Biomarker of Mortality in Kidney Transplant Waitlist Patients.

Nephrology (Carlton, Vic.)·2026
Same author

Pathomic analysis of 5-year surveillance biopsies as predictors of kidney allograft loss.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

Longitudinal Peripheral Blood Transcriptomics Reveal Novel Signatures During Cardiac Allograft Rejection.

Transplantation direct·2026
Same author

Promoting Equity in Transplant Research by Addressing the Exclusion of Patients With Glomerular Disease.

Kidney international reports·2025
Same author

Living Paired Exchange Donation: Unlocking New Horizons in Kidney Transplantation.

Mayo Clinic proceedings·2025
Same author

Early Removal of Ureteral Stents When Attached to the Foley Catheter in Living Donor Kidney Transplant Recipients Reduces Urinary Tract Infections.

Clinical transplantation·2025
Same journal

Sex differences in renal acid-base regulation.

Current opinion in nephrology and hypertension·2026
Same journal

Primary prevention of chronic kidney disease in type 2 diabetes mellitus with sodium-glucose cotransporter 2 inhibitors.

Current opinion in nephrology and hypertension·2026
Same journal

Financial and policy challenges of delivering kidney replacement therapies in resource-limited settings.

Current opinion in nephrology and hypertension·2026
Same journal

The role of kir4.1/Kir5.1 in mediating the effect of angiotensin-II on Na-Cl-cotransporter.

Current opinion in nephrology and hypertension·2026
Same journal

Role of the calcium-sensing receptor in regulating calcium transport in the thick ascending limb.

Current opinion in nephrology and hypertension·2026
Same journal

Social determinants of chronic kidney disease: from association to clinical and population action.

Current opinion in nephrology and hypertension·2026
See all related articles

ABO incompatible kidney transplantation shows promising short-term outcomes. Advances in managing rejection and cost-effectiveness suggest wider implementation for kidney transplant patients.

Area of Science:

  • Nephrology
  • Transplantation Immunology
  • Immunosuppression

Background:

  • ABO incompatible kidney transplantation is an evolving procedure.
  • Increasing recognition of its effectiveness in renal replacement therapy.

Purpose of the Study:

  • To summarize recent advances in ABO incompatible kidney transplantation.
  • To review current outcomes and future directions.

Main Methods:

  • Review of recent literature on ABO incompatible kidney transplantation.
  • Analysis of outcomes, rejection mechanisms, and cost-effectiveness.

Main Results:

  • Short to intermediate-term outcomes are favorable, with long-term data still emerging.
  • Splenectomy may be avoidable; A2 blood group incompatible transplants benefit blood group B recipients.

Related Experiment Videos

  • C4d deposition indicates acute humoral rejection; chronic rejection (transplant glomerulopathy) has long-term implications.
  • Despite increased initial costs, ABO incompatible transplantation is cost-effective compared to dialysis, considering quality of life.

    • Conclusions:

    • ABO incompatible kidney transplantation is an effective therapeutic option.
    • The procedure is poised for wider future implementation in kidney transplantation.
    • Ongoing research continues to refine protocols and improve long-term graft survival.